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Carbohydrate, protein and fat metabolism during exercise following oral 
carnitine supplementation in man. 
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Abstract: 
Twenty non-vegetarian active males were pair-matched and randomly 
assigned to receive 2 g L-Carnitine L-tartrate (LC).d-1 or placebo for 2 weeks. 
Subjects exercised for 90 min at 70% V O& 2max following 2 days of a prescribed 
diet (mean ± SD: 13.6 ± 1.6 MJ, 57% carbohydrate, 15% protein, 26% fat, 2% 
alcohol) before and after supplementation. Results indicated no change in 
carbohydrate oxidation, nitrogen excretion, branched-chain amino acid 
oxidation, or plasma urea during exercise between the beginning and end of 
supplementation in either group. Following 2 weeks LC supplementation the 
plasma ammonia response to exercise tended to be suppressed (0 vs. 2wk at 60 
min exercise: 97 ± 26 vs. 80 ± 9; and 90 min exercise: 116 ± 47 vs. 87 ± 25 
µmol.L-1), with no change in the placebo group. The data indicate that 2 weeks 
of LC supplementation does not affect fat, carbohydrate and protein 
contribution to metabolism during prolonged moderate intensity cycling 
exercise. However, the tendency towards suppressed ammonia accumulation 
indicates that oral LC supplementation may have the potential to reduce the 
metabolic stress of exercise or alter ammonia production/removal which 
warrants further investigation. 
 
 
Key Words: L-Carnitine L-tartrate, cyclists, fat oxidation, carbohydrate 
oxidation, protein utilisation. 
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The two primary, inter-related roles of L-carnitine (LC) in metabolism are to 
transport long- and medium-chain fatty acids into mitochondria for β-
oxidation (Fritz, 1963), and to buffer excess short-chain acyl groups, such as 
acetyl-CoA, thereby maintaining optimum energy flux within mitochondria 
(Constantin-Teodosiu, Cederblad & Hultman, 1992). We have previously 
observed enhanced carbohydrate (CHO) oxidation during 60 min cycling 
exercise in endurance-trained males following supplementation with L-
Carnitine (LC) for 2 weeks (Abramowicz & Galloway, 2005), whereas the 
promoted benefits of carnitine supplementation include increased fat 
oxidation. We have hypothesized that this shift in substrate utilisation 
following supplementation in trained athletes may be a result of the short-
chain acyl group buffering role of carnitine but this action could also affect 
amino acid oxidation in skeletal muscle. Furthermore, it may act in the same 
way in other metabolically active tissues such as the liver, brain, or heart thus 
influencing whole body substrate utilisation.  
To date, studies investigating the effect of LC supplementation on fuel 
utilisation during exercise have utilised gas analysis techniques, using 
calculations for CHO and fat oxidation based on a non-protein respiratory 
quotient. Protein is generally believed to contribute 5 - 10% of the total energy 
demand in prolonged exercise (Graham & MacLean, 1992), with branched-
chain amino acid (BCAA) oxidation making the major contribution. Carnitine 
has been shown to facilitate the metabolism of branched-chain amino acids in 
skeletal muscle by stimulating the conversion of branched-chain keto acids 
(BCKA) to carnitine esters (De Palo, Metus, Gatti et al., 1993; Veerkamp, 
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Van Moerkerk & Wagenmakers, 1985). In doing so, the inhibition of BCKA 
dehydrogenase, one of the primary regulators of muscular amino acid 
metabolism, is removed and free coenzyme-A is released for use in the many 
energy-producing mitochondrial reactions. It has therefore been suggested that 
supplementation with carnitine may further enhance the breakdown of BCAA 
during exercise by buffering the usual accumulation of BCKA’s (Hoppel, 
2003). Conversely, if LC supplementation were to enhance fatty acid uptake 
and metabolism during exercise, it may reduce amino acid catabolism. If 
amino acid oxidation during exercise were to change following LC 
supplementation, this would question the validity of using the non-protein 
respiratory quotient to estimate fat and CHO oxidation during exercise. To 
date, the effect of LC supplementation on amino acid contribution to 
metabolism during exercise in humans has not been investigated. 
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The aim of this study was to determine whether supplementation with L-
Carnitine L-tartrate alters the fuel contribution to metabolism in endurance-
trained male athletes and specifically to examine any changes in protein 
contribution to metabolism.  
 
Methods: 
Twenty non-vegetarian male athletes actively involved in endurance training 
were recruited. The subjects’ characteristics are shown in Table 1. All subjects 
were fully informed about the study and underwent pre-participation screening 
(medical history and physical activity questionnaires) before written informed 
consent was obtained. The study was undertaken during the early preparation 
phase of the cycling and triathlon competitive season to ensure consistent 
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endurance-based training was being undertaken. No subject was suffering 
from any metabolic disorder and none was taking any medication or 
nutritional supplements other than multivitamins/minerals or commercial 
sports drinks during training. All experimental procedures were approved by 
the University Ethics of Research Committee, and all subjects were free to 
withdraw from the study at any time without obligation. 
The study was undertaken using a double blind, placebo-controlled, pair-
matched parallel design. Pair matching was undertaken primarily on the basis 
of submaximal exercise workload and age. Subjects attended the laboratory on 
4 occasions over 4 - 5 weeks. The first visit was used to determine V O& 2max, 
power output at 70% V O& 2max, and body composition using skinfolds (bicep, 
tricep, subscapular, supraspinale, abdomen, mid thigh, calf; Norton & Olds, 
2000). The maximal test was undertaken on an electrically braked cycle 
ergometer (Lode Excalibur Sport V2.1, Lode BV, The Netherlands) in a 
laboratory where the temperature was maintained between 20-21oC.  
All subsequent exercise trials, involving 90 minutes of steady state exercise at 
70% of VO2max, were undertaken on the same day of the week and same time 
of day. In the second visit subjects undertook a familiarisation trial to ensure 
the correct power output had been selected and to familiarise subjects with all 
testing procedures. The final two visits were conducted before and after two 
weeks of LC supplementation. 
 
Supplementation 
Supplementation consisted of 2 capsules taken twice daily with breakfast and 
evening meals (i.e. 4 capsules.d-1 total) for 14 d. The supplement capsule 
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consisted of 746 mg L-Carnitine L-tartrate (L-Carnipure®, Lonza Ltd., Basel, 
Switzerland), thereby providing 2 g L-Carnitine
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.d-1 (LC). The placebo capsule 
consisted of a methyl cellulose filler of the same weight as the carnitine (P). 
Subjects’ compliance to the supplementation was assessed by checking for any 
remaining capsules at the end of 2 weeks and verbal questioning.  
 
Dietary and Exercise Controls 
Each subject was prescribed their dietary intake for 48 h prior to and 24 h post 
trial, based on attaining a minimum of 6 g carbohydrate.kg body mass (BM)-
1.d-1 and 1.5 g protein.kg BM-1.d-1 and achieving estimated energy 
requirements (Burke, 1996). These 2 d diets were designed around their 
typical dietary intake taken from a 7 d food diary. Compliance was assessed 
by using a checklist where subjects were asked to note any changes to their 
prescribed diet. Along with their prescribed diet, subjects were requested to 
undertake the same exercise in the 48 h prior to each trial to ensure that any 
differences observed in nitrogen balance could be attributed to a carnitine 
treatment effect and not to an effect of low glycogen stores (Lemon & Mullin, 
1980). 
 
The Trials 
Subjects attended the laboratory for baseline measurements before treatment 
commenced (0wk), and at the end of the two week supplementation period 
(2wk). A 24 h urine collection was commenced 24 h prior to the trial 
commencement time. Each trial was undertaken 2 h following a standardised 
meal consisting of 1 g.kg BM-1 carbohydrate (bread and jam). The last dose of 
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their supplement was taken 3 h before the exercise trial, with a small snack 
which formed part of their prescribed diet. Upon arrival at the laboratory, a 
pre-trial urine sample was collected prior to assessing nude BM, and a heart 
rate monitor supplied. Subjects then rested in a supine position whilst a 
cannula (20 gauge, SSS Healthcare) was inserted into an antecubital vein. 
Following 5 min of seated rest a blood sample was drawn without stasis, along 
with a free flowing capillary sample from a pre-heated hand for analysis of 
capillary pH, pCO
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2 and bicarbonate (Radiometer ABL 700, Copenhagen). The 
cannula was kept patent at all times using a saline flush of 1 mL following 
sample collections. Subjects then began cycling for 5 min at 50% of their 
required power output, followed by 85 min at a constant power output 
equivalent to (mean ± SD) 69.7 ± 4.4% V O& 2max, at a self-selected pedal 
cadence. Expired gas was collected over 4 min at 15-min intervals (e.g. 13-17 
min) from time zero using an online gas analysis system (Sensormedics Vmax 
29, Holland) calibrated with known gases prior to each test. Heart rate was 
recorded at 60-second intervals throughout the trial, and a rating of perceived 
exertion (RPE, 15-point Borg scale; Borg, 1982) recorded every 10 minutes 
throughout exercise. Venous blood was drawn at rest and 15, 30, 60 and 90 
min during exercise, and fingerprick capillary samples were taken from a pre-
warmed hand at rest, 30, 60 and 90 min of exercise. Water was provided 
throughout the trial, with encouragement to achieve sufficient fluid intake to 
prevent a reduction in body mass based on data collected in the familiarisation 
trials. Subjects were cooled with a fan throughout all trials. Following 
completion of the 90 min, subjects rested during the removal of the cannula, 
towel-dried, had final nude BM recorded, and emptied their bladder again for 
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sampling. For the next 22 h, subjects maintained their prescribed dietary 
intake and undertook another complete urine collection (thus completing 24 h 
from the beginning of their trial). If a subject needed to empty his bladder at 
any point during the 90 min they were allowed 2 min to attend to this, with a 
sample being drawn and the volume included in calculations of fluid loss over 
the trial, and this did not alter the total duration of activity conducted by the 
subjects. 
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Blood and Urine Analysis 
Prior to, and at 15, 30, 60 and 90 min of exercise, duplicate 100 µL aliquots of 
whole blood were immediately deproteinised in 1 mL ice-cold 0.4 M 
perchloric acid (PCA), shaken vigorously and kept on ice until centrifugation 
at 10000 rpm for 3 min. Samples were subsequently frozen at -20oC until 
analysis. Blood lactate and glycerol were measured by fluorimetric procedures 
(Jenway 6200 fluorimeter, Jenway Ltd, Essex; Boobis & Maughan, 1983; 
Maughan, 1982). The remaining blood was mixed well in EDTA tubes and 
duplicate samples were drawn into capillary tubes which were centrifuged at 
10000 rpm for microhaematocrit measurement. A further 1.5 mL portion of 
the blood sample was centrifuged before duplicate aliquots of plasma were 
drawn off for glucose and free fatty acid (FFA) analysis. Plasma glucose 
(Sigma Diagnostic), plasma FFA (Wako Chemicals, Germany) and 
haemoglobin (cyanmethaemoglobin method) were assayed within 3 h of blood 
draws using standard reagent kits (Hitachi U2001, Hitachi Instruments Ltd, 
USA). Blood and plasma volume changes were calculated from haematocrit 
and haemoglobin using standard equations (Dill & Costill, 1974). 
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Additional blood was collected into lithium heparin tubes at rest and at 60 and 
90 min exercise, centrifuged at 5000 rpm at 4
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oC for 10 min, with plasma 
extracted into duplicate tubes and frozen at -60oC until analysis. The rest and 
90 min samples were used for analysis of noradrenaline and adrenaline 
analysis by HPLC with electrochemical detection using the methodology 
outlined by Goldstein et al. (1981) and rest, 60 and 90 min samples for plasma 
carnitine fractions determination by radiometric methods using liquid 
scintillation as outlined by McGarry & Foster (1985). 
Samples for amino acid assessment (BCAA’s, alanine and glutamate) were 
prepared by mixing 80 µL plasma (from EDTA collection tube) with 20 µL 
1.375 mM internal standard 1 (L-Methionine) and 10 µL 3.3 M perchloric 
acid. This mix was immediately vortexed, then centrifuged at 1300 rpm for 10 
min. The supernatant was removed for analysis against a known standard by 
HPLC using fluorescence detection and pre-column derivitisation with 18 o-
pthalaldehyde (Hypersel amino acid method, ThermoHypersil-Keystone, 
Runcorn, UK) according to the method of Heinrikson & Meredith (1984). 
Also, duplicate 250 µL aliquots of plasma drawn from the lithium heparin tube 
were immediately frozen at -20oC until subsequent analysis for urea nitrogen 
and ammonia using Sigma Diagnostics kit 171-C for ammonia and 640-B for 
urea nitrogen (Sigma Diagnostics, St Louis MO, USA). 
Urinary carnitine excretion was determined in each treatment period by means 
of 24 h urine collections prior to and after each exercise trial. A 5 mL sample 
of mixed urine was collected and frozen at -60oC until analysis, and the total 
volume of urine excreted over the 24 h period measured to the nearest mL. 
Urinary carnitine fractions were subsequently analysed (McGarry & Foster, 
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1985). An additional 5 mL sample was drawn from every urine collection 
prior to volume measurement (including the immediate pre-exercise, 
immediate post-exercise, and any intervening collection) and was frozen at -
20
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oC until analysis for urinary nitrogen determination via the total Kjeldahl 
nitrogen in water method (Tecator application sub note ASN 3503) on a 
Tecator Kjeltec auto 1030 analyser (Foss, Denmark). 
Nitrogen balance (assuming stable sweat and faecal losses) was estimated by 
comparing the difference between 24 h prescribed dietary protein intake 
(divided by 6.25 to calculate nitrogen intake) and 24 h urinary nitrogen 
excretion, both before and after each exercise trial (Tarnopolsky, MacDougall 
& Atkinson, 1988). 
 
Statistics 
All data were checked for normality of distribution and homogeneity of 
variance prior to analysis. Within group differences were assessed using 
repeated measures analysis of variance (RMANOVA) with time and trial as 
within subjects factors. Significant main effects were then assessed using 
paired T-test with Bonferroni correction to determine at which time points the 
differences lay. Changes between 0 and 2 weeks were compared between 
groups using RM ANOVA with time as a within-subjects factor and treatment 
group as a between-subjects factor. Differences between groups were then 
assessed using independent-samples T-test with Bonferroni correction (SPSS 
version 11.0.0, SPSS Inc. 2001). Significance was accepted at p < 0.05 or 
Bonferroni adjusted value. All data are expressed as mean ± SD unless 
otherwise specified. 
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Results: 
There was no difference between 0 and 2 wk in the 2 d pre-trial or the 24 h 
post-trial diets (Table 2). Subjects were in apparent small positive nitrogen 
balance throughout all exercise trials, with no difference between 0 and 2 
week trials or between treatment groups (Table 3). 
Pre-trial training and dietary controls were effective in ensuring that there 
were no differences between trials or groups for pre-exercise plasma glucose 
(5.4 ± 1.0 and 5.5 ± 0.9 mmol.L-1 for P 0wk and P 2wk, 5.3 ± 0.7 and 5.4 ± 0.6 
mmol.L-1 LC 0wk and LC 2wk, respectively) or body mass (75.0 ± 9.8 and 
75.3 ± 9.8 kg P 0wk and P 2wk, 75.7 ± 9.3 and 75.9 ± 9.4 kg LC 0wk and LC 
2wk, respectively). Blood and plasma volume fell by the same degree (6-7% 
and 10-11%, respectively) in the first 15 min of steady state exercise (p < 
0.01), and did not change further over the duration of exercise in any trial. 
Further, no differences were found between trials or groups for body mass 
change (-0.40 ± 0.27 vs. -0.50 ± 41 kg for P 0wk and P 2wk, and -0.50 ± 0.21 
vs. -0.41 ± 0.37 kg for LC 0wk and LC 2wk, respectively) or fluid intake over 
exercise (1.34 ± 0.28 vs. 1.34 ± 0.31 L for P 0wk and P 2wk, and 1.19 ± 0.31 
vs. 1.22 ± 0.33 L for LC 0wk and LC 2wk, respectively); changes in hydration 
status over the exercise periods were therefore small (0.5%) and the same in 
each trial. Exercise HR, cadence and RPE did not differ between the 0 and 2 
wk trials within either group, although cadence was higher in the LC group 
(88 rpm) than P group (82 rpm, p < 0.05). HR and RPE increased over the 
duration of exercise (p < 0.01) whilst cadence fell (~5 rpm). 
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Haematological and Urinary Data 267 
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No differences were found for pH, pCO2, bicarbonate, glucose or FFA 
responses to supplementation between P and LC groups (Table 4). There was 
no significant change over the duration of 90 min steady state exercise for pH, 
pCO2 and plasma glucose, whereas FFA and glycerol increased progressively 
throughout exercise in all trials (p < 0.01). Mean blood lactate (Table 4) was 
below 2 mmol.L-1 in both groups at all times. There was no difference 
between groups for blood lactate at 0 weeks, nor between 0 and 2 weeks in LC 
and P groups. Blood lactate was elevated at 15 and 30 mins in the LC group at 
2 wk but did not quite reach statistical significance from 0wk. There was no 
difference for glycerol between trials in the P group, whereas in the LC group 
glycerol fell an average of 0.12 mmol.L-1 from the 0 to 2 wk trial both at rest 
and during exercise (p = 0.07). 
There was no difference in the exercise response of adrenaline (change over 
exercise, 0 wk P: 4.08 ± 3.10, 2 wk P: 3.32 ± 2.10, 0 wk LC: 3.21 ± 3.40, 2 wk 
LC: 2.06 ± 1.62 nmol.L-1) or noradrenaline between trials within either group 
(0 wk P: 8.76 ± 4.03, 2 wk P: 9.41 ± 3.73, 0 wk LC: 6.64 ± 2.37, 2 wk LC: 
6.32 ± 1.66 nmol.L-1).  
There were no between trial changes for blood concentrations of urea nitrogen, 
total BCAA or alanine in either group (Table 3). There was also no difference 
in urinary nitrogen excretion either over 24 h (Table 3) or immediately before 
to after exercise (pre-exercise: 0.7 ± 0.5 g P 0wk, 0.9 ± 0.7 g P 2wk, 1.1 ± 1.1 
g LC 0wk, 1.2 ± 1.0 g LC 2wk; post-exercise: 0.9 ± 0.6 g P 0wk, 0.9 ± 0.6 g P 
2wk, 1.1 ± 0.3 g LC 0wk, 1.2 ± 0.4 g LC 2wk). There was no change over the 
exercise period in blood BCAA or alanine concentrations, but blood urea 
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nitrogen increased progressively from 15 through to 90 min of exercise (p < 
0.01). Resting plasma glutamate was higher following 2 wk LC than 0 wk LC 
(p < 0.05), with no change between 0 and 2 wk P (Table 3). Plasma glutamate 
concentrations fell over the duration of exercise in all trials (p < 0.05). 
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Plasma ammonia increased over the exercise duration in all trials except for 
2wk LC trial. Analysis revealed that plasma ammonia concentration was 
suppressed towards the end of exercise at 2 wk in the LC group compared with 
0wk LC but this did not quite reach statistical significance (Figure 1). 
 
Substrate Metabolism:  
No significant difference was found in V O& 2, COV& 2, E or respiratory 
exchange ratio (RER) during exercise between 0 and 2 wk within either P 
(mean RER across the exercise period of 0.80 ± 0.03 and 0.80 ± 0.04 for P 
0wk and P 2wk, respectively) or LC groups (mean RER across the exercise 
period of 0.80 ± 0.05 and 0.81 ± 0.04 for LC 0wk and LC 2wk, respectively), 
and all except V CO
V&
& 2 changed across the exercise period, reflecting the 
expected cardiovascular and ventilatory drift. Due to the absence of 
differences in nitrogen balance or plasma amino acid concentrations during 
exercise as a consequence of LC supplementation, CHO and fat utilisation 
were estimated using the non-protein RER (Peronnet & Massicotte, 1991). 
There was no 0 to 2 wk trial difference in CHO oxidation between groups 
(Figure 2) although CHO oxidation was higher at all time points during 
exercise in the 2wk trial compared with 0wk trial in the LC group. There was a 
trend towards a between group difference in 0 to 2 wk changes in fat oxidation 
during the 90 min exercise (p = 0.07, Figure 3).  
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Total CHO oxidised (mean ± SD) over the exercise period was estimated to be 
139 ± 33 and 132 ± 40 g (P group) and 137 ± 36 and 147 ± 32 g (LC group) 
for 0 and 2 wk trials, respectively. For the same trials, total fat oxidised was 
estimated to be 100 ± 16 and 105 ± 16 g (P group) and 105 ± 19 and 99 ± 21 g 
(LC group) for 0 and 2 wk trials, respectively. 
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Carnitine Status 
Resting plasma total and acyl-carnitine fractions increased following 2 wk LC 
supplementation (by 61 ± 42% and 152 ± 105%, p < 0.01, respectively) with 
no change in free carnitine (17 ± 35% change, p = 0.27). There was no change 
in any of these parameters at 2 wk P. Urinary carnitine excretion increased 
following 2 wk LC supplementation (mean 6.4-fold, 25.2-fold and 1.9-fold 
increase for total, free and acyl-carnitine over 24 h in urine, p < 0.01), with no 
change in the P group.  
 
Discussion: 
By prescribing diets for 2 d prior to and 24 h after exercise and standardising 
pre-trial exercise, we have attempted to minimise the effect of factors which 
could influence substrate metabolism during exercise, such as pre-exercise 
muscle glycogen content (van Hall, Saltin & Wagenmakers, 1999), plasma 
glucose and FFA concentrations (Coyle, Coggan, Hemmert et al., 1985) and 
hydration status (Shirreffs, Armstrong & Cheuvront, 2004). Therefore, the 
absence of any differences in blood urea nitrogen, urinary nitrogen excretion, 
nitrogen balance, plasma BCAA or alanine changes over exercise provides 
strong evidence that there is no change in protein contribution to metabolism 
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following 2 weeks of LC supplementation, although this should be confirmed 
by an isotopic tracer study. The fact that there were no differences in V CO
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& 2, 
pCO2, pH and bicarbonate concentration between trials, and that V CO& 2, 
pCO2, and bicarbonate are stable across the exercise period supports our 
assumption that the RER adequately reflects the respiratory quotient, and 
relative fat:CHO oxidation during steady state exercise in the present study 
(Peronnet & Massicotte, 1991).  
The results of this study indicate no significant effect of LC supplementation 
on carbohydrate use during 90 min steady state exercise, but there was a 
tendency towards a reduction in fat oxidation. In addition, plasma glycerol 
concentration tended to be lower, and blood lactate higher, following 2 weeks 
LC supplementation, thereby supporting a tendency towards reduced 
mobilisation and/or oxidation of fatty acids. This is contrary to the promoted 
benefits of LC supplementation, but supports the trend shown by other studies 
in our laboratory following 2 weeks LC supplementation (Abramowicz & 
Galloway, 2005). Very few well controlled studies involving 2 weeks LC 
supplementation have measured expired gas during exercise with which to 
compare these results. Marconi et al. (1985) found no difference in RER 
during 120 min walking at 65% V O& 2max in competitive walkers following 4 g 
LC.d-1, nor did Vukovich et al. (1994) in participants performing 60 minutes 
of cycling exercise at 70% V O& 2max following 6 g LC.d-1 combined with a high 
fat preload. In contrast, RER was decreased (indicating higher fat oxidation) in 
competitive runners (Williams, Walker, Nute et al., 1987) and untrained males 
(Wyss, Ganzit & Rienzi, 1990) after 3 weeks LC supplementation. It is 
possible that the duration of LC supplementation influences the effects 
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observed on fuel metabolism during exercise and it has been suggested that 
periods of supplementation 8 wk or longer may be required to observe effects 
on skeletal muscle metabolism as this is the usual procedure in animal studies 
(J. Harmeyer, personal communication). Indeed, Arenas et al. (1991) observed 
that carnitine ingestion (1g twice daily over 6 months) prevented a training-
induced decrease in muscle free and total carnitine in trained athletes but to 
date no studies using shorter periods of supplementation have demonstrated 
any alteration in muscle carnitine content with oral supplementation. 
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Plasma BCAA, alanine, glutamate and blood urea nitrogen concentration 
responses to exercise were similar to those reported in other exercise trials in 
humans (De Palo et al., 1993) and with LC supplementation (Angelini, 
Vergani, Costa et al., 1986; MacLean, Spriet, Hultman et al., 1991). The 
increased plasma urea nitrogen over the exercise bouts indicate that amino 
acids were catabolised during exercise in this study (MacLean et al., 1991). 
The lack of change in urinary nitrogen excretion, which has been used to 
assess protein contribution to exercise in other studies (Lemon & Mullin, 
1980), either over the exercise period or over 24 h after exercise indicates a 
low contribution of protein to exercise (<5% total energy expenditure). This 
may be due to the fact that our subjects were endurance-trained, and because 
the prescribed diets ensured they maintained energy balance, sufficient 
carbohydrate for training needs, and a positive nitrogen balance. 
The novel finding of a tendency for blunting of ammonia (NH3) accumulation 
toward the end of prolonged endurance exercise by LC in this study is 
consistent with the findings that hyperammonemia is present in many cases of 
carnitine insufficiency (Llansola, Erceg, Hernandez-Viadel et al., 2002). LC 
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provision has also previously been shown to reduce blood and brain ammonia 
and increase glutamate concentrations, preventing the acute toxic effects of 
hyperammonemia in mice (Grisolia, O'Connor & Costell, 1984) and in 
epileptic children undergoing valproate therapy (Gidal, Inglese, Meyer et al., 
1997). However, Oyono-Enguelle et al. (1988) found no difference in 
ammonia accumulation during exercise after 4 wk supplementation with 2 g 
LC
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.d-1, which may be related to the lower exercise intensity (< 50% V O& 2max) 
and / or shorter duration (60 min) not stimulating the degree of ammonia 
production noted under our exercise conditions. The mean resting NH3 
concentrations in the current study are within the normal range of 20 - 60 µM 
(Graham, Turcotte, Kiens et al., 1997) and the elevation over exercise is 
similar to values reported during exercise of similar intensity and duration 
(Bellinger, Bold, Wilson et al., 2000; MacLean et al., 1991; Terjung & 
Tullson, 1992). This accumulation of plasma ammonia over exercise 
correlates with muscle NH3 concentration and efflux (MacLean et al., 1991). 
The primary sources of increased NH3 are believed to be from deamination of 
AMP, increased amino acid catabolism, or decreased removal, and NH3 may 
provide a marker of muscle metabolic stress because its production increases 
towards the end of endurance exercise and reflects the extent of the reliance of 
active muscle on amino acid catabolism (Terjung & Tullson, 1992) or reflects 
low glycogen levels (Sahlin & Broberg, 1990). Thus, NH3 accumulation has 
been linked with fatigue during exercise (Ogino, Kinugawa, Osaki et al., 
2000). In the absence of any change in estimated carbohydrate oxidation or 
nitrogen balance in the present study it would seem that glycogen depletion 
and/or increased catabolism of amino acids cannot explain the apparent 
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blunting of ammonia accumulation during prolonged exercise following a 
period of carnitine ingestion and this effect could therefore be linked to 
increased removal from the circulation. 
417 
418 
419 
420 
421 
422 
423 
424 
425 
426 
427 
428 
429 
430 
431 
432 
433 
434 
435 
436 
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441 
Another mechanism for an attenuated NH3 accumulation could therefore be 
through glutamate processing during exercise. Glutamate can accept an NH3 
group to form glutamine, which is then released from muscle; it can also be 
transaminated with pyruvate to form alanine, or can be deaminated, producing 
NH3 (Snow, Carey, Stathis et al., 2000). Since we also observed no change in 
alanine or BCAA oxidation, it is possible that the lower NH3 reflects an 
increased glutamine generation due to a more plentiful supply of glutamate 
precursor prior to exercise, as was observed in this study. Furthermore, plasma 
NH3 and hypoxanthine concentrations have been shown to be correlated 
(Ogino et al., 2000), and reduced hypoxanthine has been reported by Volek et 
al. (2002) following LC supplementation suggesting that carnitine can reduce 
metabolic stress. Regardless of the mechanism, lowered NH3 concentrations 
(especially towards the end of moderate-high intensity endurance exercise) 
may reflect better maintenance of the ATP:AMP ratio within exercising 
muscle or other metabolically active tissues and thus appear to be indicative of 
reduced metabolic stress during exercise. However, if it is assumed that 
muscle carnitine content did not increase in our subject group, this raises the 
possibility that the effects we have observed on ammonia accumulation are the 
result of extramuscular metabolic actions of carnitine in organs such as liver, 
kidney, heart and brain tissue which may affect ammonia production or 
removal and therefore deserve further focussed attention. 
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Conclusion: 442 
443 
444 
445 
446 
447 
448 
This study indicates that LC supplementation does not appear to alter the 
proportional contribution of protein, CHO or fat to energy metabolism during 
prolonged exercise in this well-trained endurance athlete sample. However, 
LC supplementation appears to blunt the accumulation of ammonia, which 
may reflect reduced metabolic stress in the exercising muscle or increased 
ammonia removal from the circulation and this warrants further investigation. 
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Figure 1. Plasma ammonia changes over exercise following 2 wk P (A) and LC (B) 
(mean ± SEM). 
* p = 0.03 (not statistically significant due to Bonferroni correction, p<0.01), mean 
difference (µmol.L-1) 17.1, 95% CI (0.52 to 33.73) 
† p = 0.09, mean difference (µmol.L-1) 29.4, 95% CI (-8.13 to 66.93) 
 
Figure 2. Rate of CHO oxidation during 90 min exercise in P (A) and LC (B) (mean ± 
SEM). 
 
Figure 3. Rate of fat oxidation during 90 min exercise in P (A) and LC (B) (mean ± 
SEM). 
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Table 1. Subject characteristics (mean ± SD), n = 10 in each group. 1 
2 
3 
 
CHARACTERISTIC PLACEBO LC 
Age (y) 32 ± 9 34 ± 10 
Height (cm) 179 ± 7 178 ± 4 
Body Mass (kg) 75.7 ± 10.2 76.0 ± 9.5 
Sum of Skinfolds (mm) 62 ± 26 62 ± 27 
V& O2max (L.min-1) 4.92 ± 0.46 4.96 ± 0.64 
Workload (W.kg-1) 3.1 ± 0.6 3.0 ± 0.6 
Training History (y) 8.9 ± 5.3 9.0 ± 5.9 
Current Cycle Training 
(h.wk-1) 
6.5 ± 3.6 5.1 ± 2.4 
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Table 2. Composition of prescribed diets (mean ± SD, n=10 in each group). 1 
MACRONUTRIENT 2 DAY PRE-TRIAL 24 HR POST TRIAL 
 PLACEBO LC PLACEBO LC 
Energy (MJ) 13.5 ± 1.2 13.7 ± 1.9 14.0 ± 1.9 13.2 ± 2.0 
CHO (g) 490 ± 59 499 ± 79 495 ± 68 500 ± 81 
Protein (g) 123 ± 11 122 ± 14 119 ± 14 118 ± 19 
Fat (g) 97 ± 10 91 ± 26 113 ± 26 83 ± 22 
 27
1 
2 
3 
4 
5 
6 
Table 3. Blood urea nitrogen, plasma amino acids, urinary nitrogen excretion and  
   nitrogen balance before and after 90 min exercise. 
 
Trial / Time 
(min) 
Urea N2 
(mg.dL-1) 
Total 
BCAA 
(µmol.L-1) 
Plasma 
alanine 
(µmol.L-1) 
Plasma 
glutamate 
(µmol.L-1) 
N2 
excretion 
(g in 24 h) 
N2 balance* 
(g) 
P 0wk 0 
90 
15.3 ± 2.0 
16.2 ± 1.9 
418 ± 44 
415 ± 44 
355 ± 80 
393 ± 58 
63 ± 9 
50 ± 12b
15 ± 5 
16 ± 6 
4.3 ± 4.3 
5.4 ± 5.3 
P 2wk 0 
90 
15.5 ± 2.3 
16.3 ± 2.2 
414 ± 82 
421 ± 72 
382 ± 71 
413 ± 107 
64 ± 18 
54 ± 14b
16 ± 5 
19 ± 6 
3.7 ± 4.9 
2.6 ± 6.7 
LC 0wk 0 
90 
15.0 ± 2.7 
15.7 ± 2.5 
405 ± 59 
375 ± 40 
386 ± 59 
412 ± 60 
55 ± 13 
45 ± 17b
17 ± 6 
17 ± 6 
2.5 ± 4.7 
5.1 ± 5.0 
LC 2wk 0 
90 
14.5 ± 2.5 
15.7 ± 2.5 
432 ± 109 
445 ± 154 
407 ±85 
457 ± 113 
66 ± 26a
52 ± 25b
15 ± 6 
16 ± 4 
4.3 ± 4.5 
4.9 ± 5.0 
 
* nitrogen balance data refers to 24 h pre and 24 h post exercise, not 0 and 90 min 
a greater than LC 0 wk resting value, p < 0.05 
b significant change from resting value, p < 0.05  
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Table 4: Blood pH, pCO2 (kPa), plasma bicarbonate (mM, HCO3), plasma FFA 
(mM), blood glycerol (mM), plasma glucose (mM) and blood lactate (mM) responses 
to exercise in placebo and carnitine supplemented groups 
1 
2 
3 
Variable / trial Rest 15 min 30 min 60 min 90 min 
pH P  0wk 
  2wk 
pH LC  0wk 
  2wk 
7.42 (0.01) 
7.41 (0.01) 
7.41 (0.03) 
7.42 (0.02)
- 
- 
- 
- 
7.38 (0.02) 
7.38 (0.02) 
7.39 (0.02) 
7.38 (0.03)
7.39 (0.01) 
7.39 (0.03) 
7.40 (0.03) 
7.39 (0.03) 
7.41 (0.02) 
7.39 (0.02) 
7.40 (0.03) 
7.40 (0.03)
pCO2 P 0wk 
  2wk 
pCO2 LC 0wk 
  2wk 
5.47 (0.26) 
5.48 (0.40) 
5.28 (0.35) 
5.38 (0.34)
- 
- 
- 
- 
5.52 (0.28) 
5.48 (0.44) 
5.27 (0.30) 
5.40 (0.37)
5.46 (0.34) 
5.39 (0.41) 
5.28 (0.39) 
5.35 (0.40) 
5.34 (0.34) 
5.42 (0.33) 
5.20 (0.33) 
5.24 (0.31)
HCO3 P 0wk 
  2wk 
HCO3 LC 0wk 
  2wk 
25.7 (1.0) 
25.5 (0.8) 
25.0 (1.4) 
25.7 (1.4) 
- 
- 
- 
- 
23.9 (1.3) 
23.8 (1.2) 
23.5 (1.6) 
23.5 (1.3) 
24.4 (1.1) 
24.1 (1.6) 
24.2 (1.4) 
23.9 (1.2) 
24.7 (1.2) 
24.1 (1.2) 
24.0 (1.0) 
24.1 (1.3) 
FFA P  0wk 
  2wk 
FFA LC 0wk 
  2wk 
0.28 (0.23) 
0.26 (0.13) 
0.33 (0.14) 
0.23 (0.17)
0.17 (0.13) 
0.18 (0.07) 
0.24 (0.09) 
0.18 (0.09)
0.28 (0.26) 
0.26 (0.14) 
0.37 (0.17) 
0.32 (0.13)
0.42 (0.26) 
0.42 (0.17) 
0.60 (0.29) 
0.52 (0.22) 
0.61 (0.32) 
0.54 (0.26) 
0.76 (0.32) 
0.75 (0.34)
Glycerol P 0wk 
  2wk 
Glycerol LC 0wk 
  2wk 
0.07 (0.07) 
0.10 (0.10) 
0.21 (0.13) 
0.12 (0.07)
0.12 (0.12) 
0.14 (0.11) 
0.25 (0.14) 
0.14 (0.08)
0.16 (0.11) 
0.15 (0.10) 
0.26 (0.15) 
0.17 (0.08)
0.21 (0.12) 
0.21 (0.11) 
0.34 (0.14) 
0.21 (0.06) 
0.28 (0.11) 
0.29 (0.10) 
0.42 (0.16) 
0.28 (0.11)
Glucose P 0wk 
  2wk 
Glucose LC 0wk 
  2wk 
5.41 (1.06) 
5.55 (0.83) 
5.38 (0.68) 
5.42 (0.56)
4.44 (0.59) 
4.41 (0.70) 
4.39 (0.46) 
4.23 (0.76)
4.45 (0.75) 
4.57 (0.79) 
4.56 (0.79) 
4.39 (0.60)
4.29 (0.48) 
4.52 (0.74) 
4.45 (0.55) 
4.34 (0.50) 
3.93 (0.38) 
4.20 (0.72) 
4.18 (0.51) 
4.19 (0.46)
Lactate P 0wk 
  2wk 
Lactate LC 0wk 
  2wk 
0.40 (0.33) 
0.38 (0.24) 
0.27 (0.20) 
0.26 (0.23)
1.25 (0.46) 
1.52 (0.54) 
1.49 (0.41) 
1.80 (0.71)
1.49 (0.55) 
1.33 (0.56) 
1.52 (0.26) 
1.96 (0.61)
1.14 (0.39) 
1.27 (0.69) 
1.34 (0.58) 
1.43 (0.69) 
1.25 (0.30) 
1.53 (0.32) 
1.36 (0.67) 
1.25 (0.37)
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Figure 1. 
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Figure 2. 
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Figure 3. 
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